EX-99.1 2 c11701exv99w1.htm PRESS RELEASE exv99w1
 

Exhibit 99.1
FOR IMMEDIATE RELEASE
SurModics Reports First Quarter 2007 Results
23% Growth in Non-CYPHER Revenue
EDEN PRAIRIE, Minnesota — January 24, 2007 — SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2006.
First Quarter Highlights (GAAP):
•   Revenue of $16.7 million, up 2% year-over-year
•   Operating income of $8.1 million; operating margin of 48%
•   Net income of $6.0 million
•   Diluted EPS of $0.32
•   Operating cash flow of $11.8 million
•   Non-CYPHER-related revenue increased 23% year-over-year
•   Two new licenses signed with SurModics customers
•   Four new customer products introduced
•   Completed the repurchase of $17.5 million of common stock
“SurModics is pleased to report 23% growth in non-CYPHER revenue for the first quarter of fiscal year 2007,” said Bruce Barclay, President and CEO. “Our overall performance during the period was negatively impacted by reduced penetration in the drug eluting stent market resulting from the controversy around late stent thrombosis, and as we had expected, lower R&D revenue compared to historical levels. However, we remain pleased with the progress we are making on our strategic plan for sustainable growth, and are confident in our ability to achieve our long-term goals.”
“SurModics continues to experience strong customer interest in our ophthalmology technologies, and we are making significant progress in driving these projects forward,” continued Barclay. “While R&D revenue was $0.8 million in the quarter, down from

 

 

$1.8 million a year ago, we have recently signed new R&D agreements with various ophthalmology customers totaling more than $2.5 million, with more R&D agreements expected based on current negotiations. Based on these new and expected agreements and meaningful progress on other customer projects across the business, we expect R&D revenue for all of fiscal 2007 to approximate or possibly even exceed last year’s near-record R&D revenue of $5.7 million.”
“Additionally, we continue to have encouraging customer interest in our prohealing and drug delivery polymer technologies,” continued Barclay. “Our In Vitro Technologies business had a particularly robust quarter, and our Hydrophilic Technologies business continues to do well.”
Revenue for the first quarter of fiscal 2007 was $16.7 million, an increase of 2% from $16.5 million in the year earlier period. Operating income was $8.1 million, a 5% decrease from $8.6 million in the prior year period. Net income was $6.0 million, a 4% decrease from $6.2 million in the same period last year. Diluted earnings per share was $0.32, compared with $0.33 in the first quarter of fiscal 2006. Prior year results include a $465,000, or $0.02 per diluted share, benefit related to the reversal of a tax reserve; there was no such benefit in the first quarter of fiscal 2007.
SurModics’ pipeline continues to represent significant potential. The company signed two new licenses in the first quarter, with many more potential licenses currently in negotiation. The company has a goal of 18 new licenses for fiscal year 2007, and we remain confident in our ability to achieve that objective. Our customers launched four new products in the marketplace during the quarter, bringing to 14 the number of launches achieved toward our goal of 30 launches between April 2006 and September 2007. As of December 31, 2006, SurModics’ customers had 89 licensed product classes generating royalty revenue, up from 80 in the prior-year period; the total number of licensed product classes not yet launched was 80, compared with 74 in the prior-year period; and major non-licensed opportunities totaled 80, compared with 67 a year ago. In total, SurModics now has 160 potential commercial products in development representing each of the company’s four focus markets — Cardiovascular, Ophthalmology, Orthopedics and Neurology.

 

 

SurModics’ cash and investment balance was $99.6 million as of December 31, 2006, and we have no debt. Operating cash flow for the quarter was $11.8 million, a 14% increase from $10.4 million in the prior year period. “SurModics remains in excellent financial condition,” said Phil Ankeny, Senior Vice President and Chief Financial Officer. “We were pleased to complete the repurchase of $17.5 million of stock during the quarter under the $35 million share repurchase program authorized by our Board in September. We continue to manage our expenses responsibly, without compromising our investment in R&D. Furthermore, our business development pipeline continues to grow, as we evaluate potentially compelling opportunities to grow our business and put our balance sheet to work.”
Live Webcast
SurModics will host a webcast at 5:00 p.m. ET (4:00 p.m. CT) today to discuss the quarterly results. To access the webcast, go to the investor relations portion of the company’s web site, www.surmodics.com, and click on the first quarter webcast icon. A replay of the first quarter conference call will be available by dialing 800-405-2236 and entering conference call ID 11081575. The audio replay will be available beginning at 7:00 p.m. CT on Wednesday, January 24, until 7:00 p.m. CT on Wednesday, January 31.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics’ Bravo™ drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics’ revenue is generated by royalties earned from the sale of our customers’ commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics’ web site is not part of this release or part of any filings the company makes with the SEC.

 

 

Safe Harbor for Forward Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700

 

 

SurModics, Inc.
Statements of Income
(In thousands, except per share data)
                 
    Three Months Ended  
    December 31,  
    2006     2005  
    (Unaudited)  
 
                
Revenue:
                
Royalties and license fees
   $ 13,219     $ 12,275  
Product sales
     2,726       2,347  
Research & development
     795       1,843  
 
            
Total revenue
     16,740       16,465  
 
                
Operating expenses:
                
Product
     1,086       681  
Research & development
     5,207       4,593  
Sales & marketing
     311       324  
General & administrative
     2,027       2,287  
 
            
Total operating expenses
     8,631       7,885  
 
            
Income from operations
     8,109       8,580  
 
                
Investment income
     1,329       728  
 
            
Income before income taxes
     9,438       9,308  
 
                
Income tax provision
     (3,446 )     (3,090 )
 
            
Net income
   $ 5,992     $ 6,218  
 
            
 
                
Basic net income per share
   $ 0.32     $ 0.34  
 
            
 
                
Diluted net income per share
   $ 0.32     $ 0.33  
 
            
 
                
Weighted average shares outstanding
                
Basic
     18,456       18,436  
Diluted
     18,556       18,643  
-more-

 

SurModics, Inc.
Condensed Balance Sheets
(In thousands)
                 
    December 31,     September 30,  
    2006     2006  
    (Unaudited)          
Assets
                
 
                
Current assets:
                
Cash & investments
   $ 50,375     $ 58,813  
Accounts receivable
     12,537       14,493  
Inventories
     933       952  
Other current assets
     1,992       1,838  
 
            
Total current assets
     65,837       76,096  
 
                
Property & equipment, net
     11,446       11,686  
Long-term investments
     49,243       47,758  
Other assets
     25,204       21,862  
 
                
 
            
Total assets
   $ 151,730     $ 157,402  
 
            
 
                
Liabilities & Stockholders’ Equity
                
 
                
Total current liabilities
   $ 10,052     $ 8,989  
 
                
Other liabilities
     3,357       3,210  
 
                
Total stockholders’ equity
     138,321       145,203  
 
                
 
            
Total liabilities & stockholders’ equity
   $ 151,730     $ 157,402  
 
            
-more-

 

SurModics, Inc.
Condensed Statements of Cash Flows
(In thousands)
                 
    Three months ended  
    December 31,  
    2006     2005  
    (Unaudited)  
Operating Activities
                
Net Income
   $ 5,992     $ 6,218  
Depreciation and amortization
     986       878  
Net other operating activities
     878       982  
Net change in operating assets and liabilities
     3,924       2,277  
 
            
Net cash provided by operating activities
     11,780       10,355  
 
            
 
                
Investing Activities
                
Net purchases of property and equipment
     (1,226 )     (2,823 )
Net other investing activities
     2,016       (10,051 )
 
            
Net cash provided (used) by investing activities
     790       (12,874 )
 
            
 
                
Financing Activities
                
Issuance of common stock
     1,428       359  
Repurchase of common stock
     (17,516 )     —  
Net other financing activities
     —       43  
 
            
Net cash provided (used) by financing activities
     (16,088 )     402  
 
            
 
                
Net change in cash and cash equivalents
     (3,518 )     (2,117 )
 
                
Cash and Cash Equivalents
                
Beginning of period
     3,751       3,921  
 
            
End of period
   $ 233     $ 1,804  
 
            

# # #